
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Dr. Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.
Dr. Paller discusses the findings of the clinical trial discussing the long-term effects of ixekizumab for treating psoriasis in children.





